Get the Stockscreener App
32.39
8.47%
2.53
After Hours:
32.19
-0.20
-0.62%
Bright Minds Biosciences Inc stock is traded at $32.39, with a volume of 44,680.
It is up +8.47% in the last 24 hours and down -12.13% over the past month.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$29.86
Open:
$30.4
24h Volume:
44,680
Relative Volume:
0.21
Market Cap:
$226.65M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-24.58
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
+0.34%
1M Performance:
-12.13%
6M Performance:
+2,789%
1Y Performance:
+1,407%
1-Day Range:
$29.75
$32.44
1-Week Range:
$28.21
$34.55
52-Week Range:
$0.93
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
32.39 | 226.65M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 - Seeking Alpha
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Piper Sandler - Defense World
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Piper Sandler sets $93 target for Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Predicts DRUG FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DRUG FY2025 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler - MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Learn to Evaluate (DRUG) using the Charts - Stock Traders Daily
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics - MSN
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Cantor Fitzgerald Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
HC Wainwright Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Bright Minds Biosciences (NASDAQ:DRUG) Releases Earnings Results - MarketBeat
Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase - Nasdaq
(DRUG) Long Term Investment Analysis - Stock Traders Daily
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% – Time to Sell? - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3%Time to Sell? - MarketBeat
(DRUG) Investment Analysis - Stock Traders Daily
Retail investors among Bright Minds Biosciences Inc.'s (CSE:DRUG) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Baird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform Recommendation - MSN
Bright Minds Buosciences Surges 5,900% Last Week. Attention Turning To Cybin ($CYBN) Rallying 23% On Upcoming... - Daily Scanner
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Strong-Buy" at Baird R W - MarketBeat
Bright Minds initiated at outperform by Baird, Longboard takeover cited - MSN
Bright Minds initiated at outperform by Baird, Longboard takeover cited (NASDAQ:DRUG) - Seeking Alpha
Baird assigns Outperform to Bright Minds stock, sees positive readthrough from recent M&A - Investing.com Nigeria
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Bright Minds to Present BMB-101 Epilepsy Drug Data at Major AES 2024 Conference | DRUG Stock News - StockTitan
Bright Minds Biosciences participates in a conference call with Truist - Nasdaq
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - The Manila Times
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - GlobeNewswire Inc.
RA Capital Management, L.P. Acquires New Stake in Bright Minds B - GuruFocus.com
A Billion-Dollar Private Placement Highlights Recent Insider Buying - 24/7 Wall St.
When (DRUG) Moves Investors should Listen - Stock Traders Daily
Cormorant Asset Management's Strategic Acquisition of Bright Min - GuruFocus.com
Bright Minds Biosciences Secures $35 Million Investment - Yahoo Finance
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement - The Manila Times
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):